 |
|
Development of orphan drugs for rare diseases
Han-Wook Yoo
Clin Exp Pediatr. 2024;67(7):315-327. Published online 2023 Jun 28 DOI: https://doi.org/10.3345/cep.2023.00535
|
|
Citations to this article as recorded by
 Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat
Bruno Hay Mele, Federica Rossetti, Maria Vittoria Cubellis, Maria Monticelli, Giuseppina Andreotti
Genes.2024; 15(3): 290. CrossRef Advancing orphan drug development for rare diseases
Jung Min Ko
Clinical and Experimental Pediatrics.2024; 67(7): 356. CrossRef A Rose by Any Other Name: The Long Intricate History of Localized Aggressive Periodontitis
Daniel H. Fine, Helen Schreiner, Scott R. Diehl
Pathogens.2024; 13(10): 849. CrossRef Perry Disease: Current Outlook and Advances in Drug Discovery Approach to Symptomatic Treatment
Zbigniew Gajda, Magdalena Hawrylak, Jadwiga Handzlik, Kamil J. Kuder
International Journal of Molecular Sciences.2024; 25(19): 10652. CrossRef Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in Europe
Gloria M. Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, Enrico Costa, Dinah M. Duarte, Maria E. Kalland, Eva Malikova, Darius Matusevicius, Dinko Vitezic, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Molecular Therapy.2024;[Epub] CrossRef Building advocacy into research
James F. Amatruda
Disease Models & Mechanisms.2023;[Epub] CrossRef
|